Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Simple item page
dc.contributor.authorSudha, Thangirala
dc.contributor.authorLin, Thangirala
dc.contributor.authorElmetwally, Ahmed M.
dc.contributor.authorNazeer, Tipu
dc.contributor.authorArumugam, Thiruvengadam
dc.contributor.authorPhillips, Patricia G.
dc.contributor.authorMousa, Shaker A.
dc.contributor.buuauthorYalçın, Murat
dc.contributor.departmentUludağ Üniversitesi/Veterinerlik Fakültesi/Temel Bilimler Bölümü.tr_TR
dc.contributor.orcid0000-0002-5600-8162tr_TR
dc.contributor.researcheridAAG-6956-2021tr_TR
dc.contributor.scopusid57192959734tr_TR
dc.date.accessioned2022-07-04T08:27:56Z
dc.date.available2022-07-04T08:27:56Z
dc.date.issued2014-08-01
dc.description.abstractSulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.en_US
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA (1R21CA124931-01)en_US
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) (R21CA124931)en_US
dc.identifier.citationSudha, T. vd. (2014). "Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin". Cancer Letters, 350(1-2), 25-33.en_US
dc.identifier.endpage33tr_TR
dc.identifier.issn0304-3835
dc.identifier.issn1872-7980
dc.identifier.issue1-2tr_TR
dc.identifier.pubmed24769074tr_TR
dc.identifier.scopus2-s2.0-84901494319tr_TR
dc.identifier.startpage25tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.canlet.2014.04.016
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0304383514002237
dc.identifier.urihttp://hdl.handle.net/11452/27639
dc.identifier.volume350tr_TR
dc.identifier.wos000337871000004tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Irelanden_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalCancer Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLow molecular weight heparinen_US
dc.subjectPancreatic canceren_US
dc.subjectNon-anticoagulant heparinen_US
dc.subjectAnti-canceren_US
dc.subjectTumor suppressoren_US
dc.subjectTumor survivalen_US
dc.subjectFactor pathway inhibitoren_US
dc.subjectTumor-growthen_US
dc.subjectP-selectionen_US
dc.subjectSurvivalen_US
dc.subjectAngiogenesisen_US
dc.subjectMetastasisen_US
dc.subjectEnoxaparinen_US
dc.subjectResistanceen_US
dc.subjectThrombosisen_US
dc.subjectInvasionen_US
dc.subjectOncologyen_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeGemcitabineen_US
dc.subject.emtreeLow molecular weight heparinen_US
dc.subject.emtreeSulfated non anticoagulant heparinen_US
dc.subject.emtreeTinzaparinen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeAnimal experimenten_US
dc.subject.emtreeAnimal modelen_US
dc.subject.emtreeAnimal tissueen_US
dc.subject.emtreeAntiangiogenic activityen_US
dc.subject.emtreeAntineoplastic activityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBleedingen_US
dc.subject.emtreeCancer inhibitionen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug mechanismen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeDrug sulfationen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHistopathologyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeLuminescenceen_US
dc.subject.emtreeMetastasis inhibitionen_US
dc.subject.emtreeMouseen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreePancreas canceren_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTumor necrosisen_US
dc.subject.meshAngiogenesis inhibitorsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshCell line, tumoren_US
dc.subject.meshChick embryoen_US
dc.subject.meshChorioallantoic membraneen_US
dc.subject.meshDeoxycytidineen_US
dc.subject.meshEnzyme inhibitorsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFibrinolytic agentsen_US
dc.subject.meshHeparin, low-molecular-weighten_US
dc.subject.meshHumansen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, nudeen_US
dc.subject.meshNeoplasm metastasisen_US
dc.subject.meshNeovascularization, pathologicen_US
dc.subject.meshPancreatic neoplasmsen_US
dc.subject.meshXenograft model antitumor assaysen_US
dc.subject.scopusVenous Thromboembolism; Cancer; Anticoagulant Agenten_US
dc.subject.wosOncologyen_US
dc.titleSuppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparinen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Yalçın_vd_2014.pdf
Size:
3.67 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus